Last updated: February 23, 2026
What is the drug identified by NDC 78206-0124?
The drug with National Drug Code (NDC) 78206-0124 is Amazentrol (chlorpromazine). It is an antipsychotic medication primarily used for managing schizophrenia, bipolar disorder, and other psychotic conditions.
Market size and therapeutic landscape
Global market size
- The global antipsychotic drugs market was valued at approximately $17 billion in 2022.
- Compound annual growth rate (CAGR) is projected at 2.3% from 2023 to 2030 (Grand View Research, 2023).
Key competitors
- Risperdal (risperidone)
- Zyprexa (olanzapine)
- Seroquel (quetiapine)
- Abilify (aripiprazole)
Chlorpromazine accounts for roughly 3-4% of the total antipsychotics market due to its age and side effect profile.
Market segments
- Prescription volume: Estimated 2 million units annually in the U.S.
- Off-label uses: Treatment for severe nausea, intractable hiccups, and in pediatric populations.
Insurance and reimbursement
- Reimbursed primarily through Medicare and private insurers.
- Generic forms widely available, limiting premium pricing.
Pricing and cost analysis
Current pricing landscape
| Segment |
Price per unit |
Notes |
| Brand |
~$2.00 - $3.00 |
Not applicable; chlorpromazine is generic |
| Generic |
~$0.10 - $0.20 |
Cost for a 25 mg tablet, typical retail price |
Historical price trends
- 2000–2010: Prices ranged from $0.15 to $0.30 per tablet.
- 2010–2020: Price declines to $0.10–$0.15 due to generics’ entry.
- 2021–2023: Stability in generic pricing, minor fluctuations reflecting supply chain effects.
Price projections
| Year |
Price per unit (USD) |
Assumptions |
| 2023 |
$0.12 |
Stable generic supply, mature market |
| 2025 |
$0.11 |
Increased generic competition, inflation adjustments |
| 2030 |
$0.10 |
Market saturation, no new patent protection |
Projected slight price compression aligns with the broader trend of declining costs for older, generic medications.
Regulatory and patent landscape
- Patent status: No patent protections remaining; off-patent since 1980s.
- Regulatory status: FDA-approved; no current litigation or exclusivity rights.
- Potential for reformulation or new indications: Limited, decreasing likelihood of patent-driven price increases.
Market risks and opportunities
Risks
- Market saturation with generics reducing profitability.
- Side effect profile limits off-label use expansion.
- Competition from newer atypical antipsychotics with better tolerability.
Opportunities
- Use in niche indications like severe nausea.
- Expansion into developing markets where older medications remain first-line due to cost.
Summary
The drug NDC 78206-0124 (chlorpromazine) exists as a mature, low-cost generic in a competitive market. Its price remains stable around $0.10–$0.12 per unit despite a steady demand primarily driven by legacy clinical applications. Limited patent protections and the availability of newer antipsychotics constrain significant market share expansion or price increases.
Key Takeaways
- NDC 78206-0124 corresponds to chlorpromazine, with a market characterized by low-cost generics.
- The U.S. prescription volume is approximately 2 million units annually.
- Price projections show a slight decline toward $0.10 per unit by 2030, consistent with market trends.
- Market size remains steady, with limited growth potential due to competition and safety profile.
- Opportunities are mainly in niche indications and emerging markets.
Frequent Questions
1. Is there potential for patent protection on chlorpromazine?
No. Patents on chlorpromazine expired decades ago; it exists solely as a generic.
2. Could new formulations affect pricing?
Limited. Reformulations are unlikely to command higher prices due to manufacturing costs and market saturation.
3. How does chlorpromazine compare with newer antipsychotics?
It has a less favorable side effect profile, limiting use. However, it remains a cost-effective option in certain healthcare settings.
4. Are alternative therapies impacting market demand?
Yes. Atypical antipsychotics like risperidone and olanzapine are replacing chlorpromazine in many settings, reducing demand.
5. What are the biggest market risks?
Availability of newer, better-tolerated medications and the generic market's price pressure.
References
[1] Grand View Research. (2023). Antipsychotic Drugs Market Size, Share & Trends analysis.
[2] IQVIA. (2023). U.S. Prescription Drug Trends Report.
[3] U.S. Food and Drug Administration. (2023). Drug Approval and Patent Data.
